June 13, 2025

Weight Loss Drugs Show Promise for Heart Failure

ACC statement highlights semaglutide and tirzepatide as therapies associated with improved symptoms and functional capacity in patients with heart failure with preserved ejection fraction and obesity.

Conexiant

June 12, 2025

Medical Oddities: Fight Cancer With (Sea) Cucumbers?

Sea sugars, strong feet, smarter carbs, test kits, and tea—this roundup’s got range.

Conexiant

June 11, 2025

Does COVID Vaccination Raise Miscarriage Risk?

COVID-19 vaccination during early pregnancy not associated with spontaneous abortion.

Conexiant

June 10, 2025

Structured Exercise Program Improves Survival Outcomes in Patients With Stage III or High-Risk Stage II Colon Cancer

A 3-year structured exercise program initiated soon after completion of adjuvant chemotherapy improved disease-free survival and overall survival, as well as patient-reported physical functioning and ...

The ASCO Post

June 10, 2025

Study Tests New Clot Removal Access Route

A new clinical trial is investigating whether removing clots using a modified access point can better prevent post-thrombotic syndrome in patients with extensive deep vein thrombosis.

Conexiant

June 06, 2025

Can At-Home Melatonin Testing Work?

At-home dim light melatonin onset assessments were 92% successful in youth with ADHD symptoms, regardless of symptom severity.

Conexiant

June 06, 2025

Tarlatamab Improves Survival in Resistant Lung Cancer

A multinational phase 3 trial found that tarlatamab significantly improved overall survival and reduced toxicity compared with standard chemotherapy in patients with small-cell lung cancer after progression on platinum-based therapy.

Conexiant

June 06, 2025

RSV or COVID: Which Strains the Heart?

A study of 32,960 hospitalizations finds 10.9% of patients with RSV experienced acute cardiovascular events, with significantly higher adjusted odds than boosted and unboosted COVID-19 cases.

Conexiant

June 05, 2025

SWOG S2302 Pragmatica-Lung Study Design Still Significant Even With Negative Results in Advanced NSCLC

Although the SWOG S2302 Pragmatica-Lung trial did not achieve its primary endpoint of improved overall survival with the combination of ramucirumab and pembrolizumab compared with standard-of-care tre...

The ASCO Post